“GlaxoSmithKline (GSK) has developed a division devoted entirely to bioelectronics that can be attached to nerves to regulate drugs, or even eliminate the need for them. GSK is seen as a pioneer in this space, and is partially funding development of bioelectronics via a $50 million venture fund,” according to PharmaVoice.